Analysts Set Establishment Labs Holdings Inc. (NASDAQ:ESTA) PT at $56.50

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have earned a consensus rating of “Moderate Buy” from the eight brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $66.7143.

A number of brokerages have weighed in on ESTA. BTIG Research raised their price objective on Establishment Labs from $62.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday. Canaccord Genuity Group increased their target price on Establishment Labs from $60.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday. Citigroup reissued a “neutral” rating on shares of Establishment Labs in a research note on Tuesday, October 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Establishment Labs in a research note on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Sunday, October 19th.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $64.91 on Friday. The company has a 50-day simple moving average of $43.66 and a 200-day simple moving average of $40.16. The company has a debt-to-equity ratio of 9.71, a current ratio of 2.84 and a quick ratio of 1.67. The company has a market cap of $1.88 billion, a PE ratio of -22.86 and a beta of 0.98. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $65.10.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.16. The firm had revenue of $53.78 million for the quarter, compared to analyst estimates of $52.28 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 201.85%. Establishment Labs’s revenue was up 33.8% compared to the same quarter last year. During the same quarter last year, the business earned ($0.59) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Establishment Labs will post -2.41 earnings per share for the current year.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds have recently made changes to their positions in the stock. State of Wyoming acquired a new stake in shares of Establishment Labs during the 3rd quarter worth $71,000. ANTIPODES PARTNERS Ltd purchased a new stake in Establishment Labs during the first quarter valued at about $81,000. Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the last quarter. CWM LLC increased its stake in Establishment Labs by 45.9% during the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after acquiring an additional 686 shares during the last quarter. Finally, Brian Low Financial Group LLC purchased a new position in shares of Establishment Labs in the 3rd quarter worth about $223,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.